eXegenics Inc Form 4 March 29, 2007

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB Washington, D.C. 20549

OMB APPROVAL

Number:

Expires:

3235-0287 January 31,

2005

0.5

Estimated average

burden hours per response...

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

Form 4 or Form 5 obligations may continue. See Instruction

Check this box

if no longer

subject to

Section 16.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

SECURITIES

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * Eichler David A

(First)

(State)

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to Issuer

eXegenics Inc [EXEG]

(Check all applicable)

(Last)

(Middle)

3. Date of Earliest Transaction (Month/Day/Year)

X_ Director Officer (give title

10% Owner Other (specify

625 AVENUE OF THE AMERICAS 03/27/2007

below) 6. Individual or Joint/Group Filing(Check

4. If Amendment, Date Original

Filed(Month/Day/Year)

Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

Person

(Street)

(City)

NEW YORK, NY 10011

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of 2. Transaction Date 2A. Deemed Security (Month/Day/Year) Execution Date, if (Instr. 3)

(Month/Day/Year)

(Zip)

4. Securities TransactionAcquired (A) or Code Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5)

5. Amount of Securities Beneficially Owned Following

6. Ownership 7. Nature of Form: Direct Indirect (D) or Indirect Beneficial Ownership (Instr. 4) (Instr. 4)

Reported (A) Transaction(s) or (Instr. 3 and 4)

Code V Amount (D) Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of 3. Transaction Date 3A. Deemed 5. Number of 6. Date Exercisable and 7. Title and An 4 Derivative Conversion (Month/Day/Year) Execution Date, if TransactionDerivative **Expiration Date** Underlying Sec Security or Exercise Code Securities (Month/Day/Year) (Instr. 3 and 4) (Month/Day/Year) (Instr. 3) Price of (Instr. 8) Acquired (A) or

Edgar Filing: eXegenics Inc - Form 4

	Derivative Security			Disposed of (Disposed of (Instr. 3, 4, and				
			Code	V (A)	(D) Date Exercisable	Expiration Date	Title	P N
Series C Convertible Preferred Stock	\$ 0	03/27/2007	<u>J(1)</u>	90,815	(2)	<u>(2)</u>	Common Stock	
Warrant (Right to Buy)	\$ 0.002	03/27/2007	<u>J(1)</u>	1,135,188	<u>(4)</u>	03/27/2017	Common Stock	
Warrant(Right to Buy)	\$ 0.6728	03/27/2007	J <u>(1)</u>	309,737	<u>(4)</u>	03/27/2017	Common Stock	
Warrant (Right to Buy)	\$ 0.8473	03/27/2007	J <u>(1)</u>	309,737	<u>(4)</u>	03/27/2017	Common Stock	
Warrant (Right to Buy)	\$ 1.0466	03/27/2007	J <u>(1)</u>	309,737	<u>(4)</u>	03/27/2017	Common Stock	
Stock Option (Right to Buy)	\$ 0.04	03/27/2007	J <u>(1)</u>	25,947	<u>(5)</u>	11/08/2014	Common Stock	
Stock Option (Right to Buy)	\$ 0.04	03/27/2007	J <u>(1)</u>	103,788	<u>(5)</u>	02/15/2015	Common Stock	
Stock Option (Right to Buy)	\$ 0.05	03/27/2007	J <u>(1)</u>	155,682	<u>(6)</u>	02/28/2016	Common Stock	

Reporting Owners

Reporting Owner Name / Address	Relationships				
• 0	Director	10% Owner	Officer	Other	
Eichler David A 625 AVENUE OF THE AMERICAS NEW YORK, NY 10011	X				

Signatures

/s/ David A. Eichler	03/29/2007		
**Signature of	Date		

Reporting Owners 2

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) All securities described were acquired in a merger transaction between Acuity Pharmaceuticals Inc. and eXegenics Inc.
- (2) These shares are currently exercisable and do not expire.
- (3) As Managing Director of Psilos Group Investors II-S, LLC, the General Partner of Psilos Group Partners II SBIC, L.P.
- (4) These warrants are currently exercisable.
- (5) These options are fully vested.
- (6) 56,218.83 of these options are fully vested. The balance will vest monthly until fully vested in December 2009.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.